Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: eculizumab
Trade Name: Soliris
Date Designated: 04/29/2009
Orphan Designation: Treatment of atypical hemolytic uremic syndrome
Orphan Designation Status: Designated/Approved
Alexion Pharmaceuticals, Inc.
121 Seaport Boulevard
Boston, Massachusetts 02210
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: eculizumab
Trade Name: Soliris
Marketing Approval Date: 09/23/2011
Approved Labeled Indication: For the treatment of atypical Hemolytic Uremic Syndrome (aHUS)
Exclusivity End Date: 09/23/2018 
Exclusivity Protected Indication* :  
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-